Causal insights on targets and populations.

Why Pheiron and Why Now?

Drug development is broken: Over 90% of drug development programs entering clinical development fail, costing the industry an average of $6.16bn for a novel approved drug. The root of the problem? Insufficient evidence to anticipate clinical efficacy. We build Pheiron to change that - in silico and at scale.